BridgeMD
New treatment option for Lower Extremity Explosive Power Deficit
Official title Effect of Ischemic Preconditioning on Lower Extremity Motor Ability and Recovery in Basketball Players During Post-Match Recovery Period
ClinicalTrials.gov ID: NCT07604948
What this study is testing
- What it's testing
- This study aimed to evaluate the effects of ischemic preconditioning on lower limb explosive power and post-exercise recovery in basketball players during a 6-week post-season recovery training period. Thirty-four male collegiate basketball players were randomly assigned to either an IPC group or a placebo control group.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 25, men only. Healthy volunteers may be eligible.
You may be able to join if
- Male basketball students at Guangzhou Sport University.
- Regular participants in basketball training/practice.
- Healthy adults without cardiovascular, hepatic, renal, digestive, neurological, or metabolic diseases.
- Blood pressure within normal range.
- No history of lower extremity musculoskeletal injury within the past 6 months.
You likely can't join if
- Presence of acute or chronic diseases affecting exercise performance.
- History of deep vein thrombosis or coagulation disorders.
- Presence of skin lesions or infections at the thigh cuff placement site.
- Participation in other concurrent lower extremity strength/power training programs outside the study.
- Use of dietary supplements known to affect muscle metabolism within 4 weeks prior to enrollment.
- Inability to complete the full 6-week intervention and testing protocol.
See the full eligibility criteria
- Male basketball students at Guangzhou Sport University.
- Regular participants in basketball training/practice.
- Healthy adults without cardiovascular, hepatic, renal, digestive, neurological, or metabolic diseases.
- Blood pressure within normal range.
- No history of lower extremity musculoskeletal injury within the past 6 months.
- Not currently using any performance-enhancing substances or medications affecting hormones/metabolism.
- Voluntary participation with signed informed consent.
- Presence of acute or chronic diseases affecting exercise performance.
- History of deep vein thrombosis or coagulation disorders.
- Presence of skin lesions or infections at the thigh cuff placement site.
- Participation in other concurrent lower extremity strength/power training programs outside the study.
- Use of dietary supplements known to affect muscle metabolism within 4 weeks prior to enrollment.
- Inability to complete the full 6-week intervention and testing protocol.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years to 25 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.